Motility & Functional GI · Article 120

What Are the Best Current Treatments for Gastroparesis?

Gastroparesis treatment requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

Gastroparesis treatment clinical reference — Related free clinical resource: Clinical Pharmacology.

Gastroparesis treatment: practical clinical approach

This page focuses on Gastroparesis treatment with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for Gastroparesis treatment

Clinical takeaway: For Gastroparesis treatment, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: Gastroparesis treatment should begin with nutrition, removal of aggravating drugs and management of diabetes, then use symptom-directed pharmacotherapy. The 2025 AGA guideline supports metoclopramide and erythromycin as initial pharmacologic options, while recommending against routine first-line use of several other agents. Refractory patients require reassessment of the diagnosis and nutritional status before pyloric intervention or gastric electrical stimulation is considered. G-POEM and device-based therapy should be selective rather than routine.

Nutrition is first-line treatment

Small, frequent meals with reduced particle size and lower fat/fiber content can improve tolerance. Liquid calories may empty more easily than solids. Patients with weight loss, micronutrient deficiency or repeated admissions need dietitian involvement. Severe disease may require jejunal feeding; parenteral nutrition is reserved for exceptional circumstances.

Use prokinetics thoughtfully

Metoclopramide remains the best-established first-line prokinetic in the United States, balanced against neurologic adverse effects and regulatory duration warnings. Erythromycin can accelerate emptying but tachyphylaxis limits long-term efficacy. Domperidone can be useful where available but is not favored as routine first-line therapy in the 2025 AGA guideline.

Treat the dominant symptom

Antiemetics can reduce nausea/vomiting even if they do not improve emptying. Abdominal pain should not be treated with opioids, which worsen gastric emptying and can create dependence. Glycemic control can reduce symptom variability in diabetic gastroparesis.

Procedures are for selected refractory disease

Before G-POEM, pyloroplasty or gastric electrical stimulation, reconfirm delayed emptying, review medication effects and verify that medical/nutritional therapy has been optimized. The 2025 AGA guideline advises against routine use of G-POEM or gastric electrical stimulation for all refractory patients, emphasizing individualized selection and shared decision-making.

Practical clinical algorithm

Confirm the diagnosis and stop/reduce medications that worsen gastric emptying when possible.
Implement small-particle, lower-fat nutrition with dietitian support if nutritional risk exists.
Optimize diabetes control and use metoclopramide or short-term erythromycin when appropriate.
Add symptom-directed antiemetics; avoid opioids.
If symptoms remain severe, reassess diagnosis, nutrition and psychological/behavioral mimics.
Refer highly selected refractory patients to a motility/advanced endoscopy center for discussion of G-POEM, surgery or gastric electrical stimulation.

Common mistakes to avoid

Jumping to G-POEM before confirming objective delayed emptying.
Using opioids for chronic gastroparesis pain.
Keeping patients on a nutritionally inadequate ‘gastroparesis diet.’
Assuming a prokinetic must normalize emptying to improve symptoms.
Failing to reassess medication-induced delayed emptying.

Trainee takeaway

Gastroparesis treatment is layered: nutrition and cause correction first, then prokinetic and antiemetic therapy, then selective advanced procedures for genuinely refractory disease.

Frequently asked questions

Is metoclopramide still first-line?

Yes. It remains a principal evidence-based option, but neurologic risks and duration of therapy require discussion and monitoring.

What about domperidone?

It can be effective where available, but the 2025 AGA guideline does not favor it as routine first-line therapy.

Who should get G-POEM?

A carefully selected patient with confirmed, medically refractory gastroparesis after reassessment at an experienced center—not every patient with persistent symptoms.

References

1. Thomson ABR. Clinical Pharmacology. CAPstone Academic Publishers; 2024.

2. Thomson ABR. Practice Review in Gastroenterology. CAPstone Academic Publishers; 2014.

3. Staller K, Parkman HP, Leiman DA, et al. AGA Clinical Practice Guideline on the Management of Gastroparesis. Gastroenterology. 2025. doi:10.1053/j.gastro.2025.08.004.

4. Camilleri M, Kuo B, Nguyen L, et al. ACG Clinical Guideline: Gastroparesis. Am J Gastroenterol. 2022;117:1197-1220.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions